④#順天堂大学 #綿田裕孝 先生 #膵β細胞不全 へのアプローチ:糖尿病の根治治療を目指して 1型糖尿病の場合、海外では既に膵島抗体陽性•未発病者に対する免疫療法(発症予防)が行われ、NEJMに抗CD3抗体(テプリズマブ)投与による発症予防が報告されたのは記憶に新しい https://t.co/w124IVyfJo https://t.co/qWWxvMKKEw
2. What would the intervention be? Lessons from other autoimmune diseases; 🍾Anti-CD3 for 14 days reduced the risk of developing type I diabetes (HR 0.41) https://t.co/KCQ6dosADG 🌧️ Hydroxychloroquine did not prevent development of RA in the STOP RA trial h
Fantastic resource launched today to de-code research. Read up on the teplizumab research trial - teplizumab was given to people with stage 2 T1D and delayed T1D onset by 2-3 years: https://t.co/Q5crWnrpwr Trial: https://t.co/SBrV8i8t0U @DUK_research
Teplizumab is used for "stage 2" type 1 diabetes in individuals who are 8 years old or older. Stage 2 T1DM is characterized by the presence of two or more autoantibodies and mild glucose abnormalities, but no symptoms. #MedTwitter #Endotwitter https:/